Oncology research company Charm Therapeutics has signed for B900 at the Babraham Research Campus in Cambridge.
The 13,569 sq ft facility will be used as a new research and development site to support the company’s growth plans.
The move follows relocation of the building’s former tenant, Bicycle Therapeutics, to Granta Park.
Babraham Research Campus is a home to more than 60 companies co-located with the Babraham Institute.
Dutch property investor and developer Kadans Science Partner acquired B900 in 2019, marking its first step into the Cambridge life science market.
Katie Nelson, senior asset manager at Kadans, said: “Charm is an example of what Kadans can do working with our tenants to provide them facilities.”
Sarah Skerratt, senior vice president and head of drug discovery at Charm, said: “This move marks an important milestone for our organisation as we continue to expand and advance our drug discovery programmes. We are grateful to Kadans for their collaboration and partnership in providing us with this facility.”
To send feedback, e-mail evelina.grecenko@eg.co.uk or tweet @Gre_Eve or @EGPropertyNews
Photo © Kadans Science Partner
